by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Wool Stocktake : AWI Annual Report 2015-16
• An additional baiting option for reducing wild dog and fox numbers is now available to woolgrowers and other landholders across Australia. Para- aminopropiophenone (PAPP) is a new chemical (toxin) that is now being manufactured and sold in baits by Animal Control Technologies Australia Pty Ltd (ACTA) under the product names DOGABAIT® for wild dog control and FOXECUTE® for fox control. PAPP was developed with funding support from AWI and is designed to allow baiting to still be an option in places where 1080 use is restricted, or for land managers who would prefer not to use 1080. PAPP also has an antidote in the event that a non-target animal such as a working stock dog is accidentally poisoned. Known as ‘Blue Healer’, the antidote can only be administered by a registered veterinarian, and must be delivered within 30 minutes of the dog eating the bait. DOGABAIT is commercially available in pails of 10 baits (total 600g) or 50 baits (total 3kg). PROGRAM 3: INVASIVE HUSBANDRY INVESTMENT FOCUS • New knowledge on analgesic options for sheep for development by the commercial pharmaceutical and veterinary sector. • Delivery of new knowledge on the timing (relative to age/size) of existing husbandry procedures and extension to stakeholders to inform welfare best practice. STRATEGIC TARGETS Targets for three-year period 2013/14 to 2015/16 Progress during 2015/16 Deliver a significant reduction in adverse welfare response from current technologies within best practice by 2017. Achieved. Buccalgesic, a pain relief paste, placed into the space between the lower molars and cheek has shown to improve animal welfare responses following castration, tail docking and mulesing. Develop pain relief alternatives with a maximum added cost of 50 cents per head per application by 2017. Partly achieved. A meloxicam product Buccalgesic is planned to be registered by the APVMA and will be available to woolgrowers as a S4 in late 2016, for a cost of around 45 cents per head. Another meloxicam based product Metacam was registered and approved by the APVMA in April 2016. KEY RESULTS DURING 2015/16 • Following on from earlier studies showing good pain relief outcomes using a meloxicam based product (Buccalgesic) with castration and tail docking, further welfare trials were conducted assessing the benefits with mulesing. The mulesing trial compared a topical local anaesthetic (Tri- Solfen), with the non-steroidal anti-inflammatory drug (Buccalgesic) along with the combined use of both products, with encouraging results to date. Further trials are planned comparing options for sheep treated with the Liquid Nitrogen Process. • Work was undertaken to support the broadening of registered use purposes of local anaesthetic pain relief products to include shearing cuts. • R&D into the relative size and age of mulesing continues. • See Program 1: Parasites & Diseases (page 11) for alternative options to mulesing. The meloxicam product Buccalgesic being applied to the internal cheek of a lamb during trials, to provide pain relief during marking. 14 REPORT OF 2015/16 OPERATIONS – ON-FARM R&D
AWI Annual Report 2014-15
AWI Annual Report 2016-17